相关实验视频
Updated: Jan 11, 2026

08:01
The Soft Agar Colony Formation Assay
Published on: October 27, 2014
113.5K
佩奥尼佛林通过中断FGF2-FGFR2-PI3K轴来抑制非小细胞肺癌
Xuexue Shao1, Bojiao Ding2, Miaomiao Gao3
1Key Laboratory of Phytomedicinal Resources Utilization, Ministry of Education, Shihezi University, Xinjiang, China.
Toxicon : official journal of the International Society on Toxinology
|November 14, 2025
概括
作为一种天然化合物,Paeoniflorin通过向FGF2和FGFR2.2,有效地抑制非小细胞肺癌 (NSCLC). 这种自然疗法抑制瘤生长,并通过PI3K/AKT通路促进细胞亡.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 非小细胞肺癌 (NSCLC) 是癌症死亡的主要原因.
- 佩奥尼佛洛林显示出抗瘤特性,但其在NSCLC中的机制尚未完全理解.
研究的目的:
- 阐明 paeoniflorin 抑制 NSCLC 的机制.
- 为了调查paeoniflorin对FGFR2的向及其下游效应.
主要方法:
- 使用了细胞测试和动物实验.
- 技术包括CETSA测定,RNA测序和西式涂抹.
- 研究了FGF2介导的PI3K/AKT通路和自调节.
主要成果:
- 氨酸直接准FGF2,抑制FGFR2的表达,并抑制下游的信号传输.
- 佩奥尼佛林逆转了PI3K/AKT通路激活,并与PI3K/AKT抑制剂协同作用.
- 佩奥尼佛洛林调节了自生物标志物,触发了亡.
结论:
- 佩奥尼佛洛林是NSCLC的新型治疗剂,抑制生长并促进亡.
- 该机制涉及抑制FGF2介导的PI3K-AKT-mTOR信号轴,并诱导自调节的亡.
- 佩奥尼弗洛林显示出作为向治疗的潜力,可能与FGF2向治疗相结合.
更多相关视频
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
447
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
447
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K

